News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
科倫博泰生物(06990.HK)SKB118新藥臨床試驗申請獲內地批准
科倫博泰生物(06990.HK)公布，已收到國家藥監局藥品審評中心同意程序性細胞死亡蛋白－1(PD-1)x血管內皮生長因子(VEGF)雙特異性抗體SKB118 (亦稱CR-001)新藥臨床試驗(IND)申請的臨床試驗通知書，用於治療晚期實體瘤。(jl/da)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
科倫博泰生物(06990.HK)SKB118新藥臨床試驗申請獲內地批准
Close
Recommend
1
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

科倫博泰生物(06990.HK)  -8.400 (-1.823%)    Short selling $67.62M; Ratio 22.800%   公布，已收到國家藥監局藥品審評中心同意程序性細胞死亡蛋白－1(PD-1)x血管內皮生長因子(VEGF)雙特異性抗體SKB118 (亦稱CR-001)新藥臨床試驗(IND)申請的臨床試驗通知書，用於治療晚期實體瘤。(jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.